Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) covers the reporting period ending January 5, 2024. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock price rather than financial performance metrics.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq listing requirements. Specifically, the company regained compliance with the $1 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This follows a prior notification on December 29, 2022, indicating non-compliance due to the stock trading below $1 for 30 consecutive business days. Nasdaq confirmed that from December 7, 2023, through January 5, 2024, the closing bid price remained at or above $1 per share.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks and contingencies. The document serves solely to notify investors of the resolution of the previous delisting risk associated with the minimum bid price rule.
Investor Verification Checklist
- Verify the current trading price of PAVM common stock to ensure continued compliance with the $1 minimum bid price requirement.
- Confirm the status of Series Z Warrants (PAVMZ) listed on the Nasdaq Capital Market.
- Review subsequent filings for any new notices from Nasdaq regarding other listing standards (e.g., market value of listed securities or shareholder equity).